Company Profile

3P Biotechnologies Inc
Profile last edited on: 8/16/2022      CAGE: 5KJ71      UEI: HSCNW2K7VN9

Business Identifier: Using plant bioactives and novel delivery systems for treatment of cancer and other chronic diseases.
Year Founded
2013
First Award
2012
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3205 Hidden Springs Lane
Prospect, KY 40059
   (502) 523-9751
   rcgupta@louisville.edu
   www.3pbiotechnologies.com/
Location: Single
Congr. District: 04
County: Jefferson

Public Profile

3P Biotechnologies, Inc. organizes around identification of plant bioactives and novel delivery systems dsseigned to yield health-beneficial effects and provide efficacy to people at high risk of cancer and other chronic diseases, via non- or minimally-intrusive measures. With the firm anchored in the belief of the intrinsic value of using natural products to Prevent disease and thereby Protect and Promote health – hence, the name “3P”, the company is currently advancing three platforms: Two involve drug delivery technologies and a third uses a methodology developed by 3P to isolate plant bioactives such as anthocyanidins for use in pharmaceuticals, nutraceuticals, cosmeceuticals, and foods and beverages. 3P’s proprietary technology can also enrich other plant bioactives such as lutein, green tea polyphenols, ellagitannins and cytotoxic withanolides.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $264,507
Project Title: Engineered Exosomes for Targeted Delivery of the CRISPR/Cas9 Genome-editor
2018 2 NIH $1,719,681
Project Title: Exosomal Drug Delivery
2014 1 NIH $225,000
Project Title: Exosomal Drug Formulations
2013 2 NIH $298,171
Project Title: Sustained, Target Delivery For Treatment Of Cervical Pathologies

Key People / Management

  Ramesh C Gupta -- Founder and President

  Niti Gupta -- Director of Finances and Administration

  Al Poskanzer -- Director of Strategic Partnerships

  Joan Simunic -- Patent Attorney & Legal Advisor

  Wendy Spencer -- Chief Operating Officer

Company News

There are no news available.